Related Experiment Video

Updated: Jul 1, 2026

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
15:45

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice

Published on: February 10, 2013

Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol

Hamza Duygu1, Ugur Turk, Oner Ozdogan

  • 1Department of Cardiology, Ege University Medical Faculty, Izmir, Turkey. hamzakard@yahoo.com

Cardiovascular Therapeutics
|September 13, 2008
PubMed

Insights

Levosimendan improved left ventricular (LV) function in heart failure (HF) patients on carvedilol, unlike dobutamine. This study highlights differing effects of inotropic agents in HF patients with beta-blocker treatment.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers are crucial for heart failure (HF) management, yet decompensation still occurs.
  • Levosimendan and dobutamine are used for decompensated HF, but their comparative effects on left ventricular (LV) function in patients on beta-blockers are not well-understood.

Purpose of the Study:

  • To compare the effects of dobutamine and levosimendan on LV systolic and diastolic functions.
  • To evaluate these effects in chronic HF patients receiving long-term carvedilol treatment.

Main Methods:

  • A randomized, open-label study involving 40 patients with chronic HF (NYHA class III-IV, LVEF <40%) on carvedilol.
  • Echocardiographic assessment of LV ejection fraction (LVEF), mitral inflow, annular velocities, and pulmonary artery pressure before and 24 hours after treatment.

Main Results:

  • Levosimendan significantly improved LVEF, mitral inflow, deceleration time, early diastolic annular velocity, and reduced pulmonary artery pressure.
  • Dobutamine did not significantly alter LV function parameters or pulmonary artery pressure.
  • Levosimendan maintained stable hemodynamics, while dobutamine increased heart rate and blood pressure.

Conclusions:

  • Dobutamine and levosimendan exert distinct effects on LV function in patients on chronic carvedilol.
  • These findings are critical for selecting appropriate inotropic therapy in decompensated HF patients undergoing long-term carvedilol treatment.
Abstract

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...